(Q34641024)

3 August 2017

title

Iloperidone, asenapine and lurasidone: a primer on their current status (English)

1 reference

3 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

2

Stephen M Stahl

1 reference

3 August 2017

Frank I Tarazi

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

31 July 2012

1 reference

Expert Opinion on Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

13

1 reference

3 August 2017

issue

13

1 reference

3 August 2017

page(s)

1911-1922

1 reference

The burden of schizophrenia on caregivers: a review

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Clozapine. A novel antipsychotic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Clozapine safety, 35 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Effects of newer antipsychotics on extrapyramidal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Antipsychotic induced weight gain in schizophrenia:mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

The metabolic syndrome and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Iloperidone binding to human and rat dopamine and 5-HT receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine effects in animal models of psychosis and cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Differential regional and dose-related effects of asenapine on dopamine receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine induces differential regional effects on serotonin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

An assessment of iloperidone for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Lurasidone: a new drug in development for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Identifying functional neuroimaging biomarkers of bipolar disorder: toward DSM-V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Agomelatine for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

The serotonin-1A receptor in anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

5-HT(1A) receptor function in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Therapeutic options for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.712114

10.1517/14656566.2012.712114

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference